REGN-EB3: First Approval

Markham, A

Markham, A (corresponding author), Springer Nat, Mairangi Bay,Private Bag 65901, Auckland 0754, New Zealand.

DRUGS, 2021; 81 (1): 175

Abstract

REGN-EB3 (INMAZEB(R), Regeneron Pharmaceuticals) is a combination of three fully-human monoclonal antibodies-atoltivimab (REGN3470), maftivimab (REGN3......

Full Text Link